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THE interaction between PAF and human platelet
membranes was investigated by measuring the steady-
state fluorescence anisotropy and fluorescence decay of
1 (4 trimethylammoniumphenyl) 6 phenyl 1,3,5 hexa-
triene (TMA-DPH) incorporated in platelet plasma
membranes. PAF induced a time-limited and significant
increase of the lipid order in the exterior part of the
membrane and a decrease in membrane heterogeneity.
These changes were blocked in the presence of the PAF
antagonists, L-659,989 and 1-O-hexadecyl-2-acetyl-sn-
glycero-3-phospho(N,N,N-trimethyl)hexanolamine.H20.
These results indicate that the observed changes in the
physico-chemical properties of the membrane are attri-
buted to the PAF-receptor interaction and signal
transduction.
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Introduction
Platelet-activating factor (PAF, 1-O-alkyl-2-O-
acetyl-sn-glyceryl-3-phosphocholine) is a potent
lipid mediator with a wide variety of biological
activities. Studies have demonstrated that PAF is
involved in various physiological and pathological
events.
1-s Many cell types are targets for PAF
activation. These include human platelets, granulo-
cytes, lymphocytes, endothelial cells and spermato-
zoa.>5 In platelets, PAF interacts with its specific
receptor in the membrane initiating a series of
biochemical events associated with the signal
6 transduction process.
This study was performed to discern the effect of
PAF on the physico-chemical organization of
human platelet membranes. The steady-state
fluorescence anisotropy of TMA-DPH incor-
porated into platelet membranes was measured
before and after the addition of PAF in the absence
or presence of two PAF antagonists, 1-O-
hexadecyl-2-acetyl-sn-glycero-3-phospho(N,N,N-
trimethyl)hexanolamine.H20 and (__+)-trans-2-(3-
methoxy- 5 methylsulphonyl-4-propoxyphenyl)- 5
(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-
659,989). We have also studied the influence ofPAF
on the fluorescence decay of TMA-DPH which is
sensitive to the membrane heterogeneity as
previously described.
7
Materials and Methods
Preparation of platelets: 10 ml of freshly drawn
acid-citrate-dextrose anticoagulated blood was
centrifuged at 120 x g for 15 min at 37C to
prepare platelet rich plasma. Platelets were isolated
and washed according to Kubina et al. Platelets
were finally resuspended in Tyrode’s buffer
(137 mM NaC1, 2 mM KC1, 12 mM NaHCO3, 0.3
mM NaH2PO4, 1 mM MgC12, 2 mM CaC12, 5 mM
glucose) with 0.1% bovine serum albumin and
apyrase (Sigma Chemical Co., St Louis, MO).
The total platelet count was obtained using a
Sysmex E-2500 blood analyser. The platelet
suspension was adjusted to a concentration of
4 108/ml. Phase-contrast microscopy (Diaplan,
Leica, Milan, Italy) showed that, under the
conditions used, control and TMA-DPH platelets
remained discoid and functional, being sensitive to
thrombin (1 U/ml). Platelets were immediately
used for fluorescence measurements. Labelling was
carried out in the dark. To a 2.5 ml quartz cuvette
containing 2 ml Tyrode’s buffer, TMA-DPH was
added to give a final concentration of I #mol/1. An
aliquot of the platelet suspension was added to give
a final concentration of 107 platelets/ml. Platelets
were activated by addition ofPAF (Sigma Chemical
Co., St Louis, MO, USA) at a final concentration
of 10-7M as previously described.
9 The PAF
antagonist, L-659,989 (kindly donated by Dr W. H.
Parsons, Merck Sharp & Dohme Research
Laboratories, NJ, USA) was added at a final
concentration of 10
-6 M. The PAF analogue
1-O- hexadecyl- 2- acetyl sn- glycero 3 phospho-
(N,N,N-trimethyl)hexanol-amine.H20 (Nova-Bio-
chem, Switzerland) was added at a final concentra-
tion of 4 x 10
-6 M. 11
Fluorescence studies: Steady-state fluorescence aniso-
tropy (rs) measurements were performed at 37C
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with a Perkin Elmer Spectrofluorimeter MPF-66,
equipped with a Perkin Elmer 7300 Personal
Computer for data acquisition and elaboration,
using TMA-DPH (Molecular Probes Inc., Eugene,
OR, USA) as a hydrophobic fluorescent probe as
previously described.
12 The computer program
calculated fluorescence anisotropy by using the
expression (Ill- I+/- x g))/(Ill + (2I+/- x g)) where g
is an instrumental correction factor, Iii and I+/- are
respectively the emission intensities with the
polarizers parallel and perpendicular to the
direction of the polarized exciting light. Fluor-
escence lifetime measurements were performed as
previously described
13 with a multifrequency phase
fluorometer. The instrument was equipped with an
ISS-ADC interface for data collection and analysis;
the excitation wavelength was set at 325 nm
(ultraviolet line of a helium/cadmium laser, Liconix
Model 4240 NB). The range of modulation
frequencies used for TMA-DPH was 7-130 MHz.
Data were accumulated at each modulation
frequency until the standard deviations of the phase
and modulation values were below 0.1 and 0.002,
respectively. The fluorescence was measured
through a long-pass filter (type RG 370 from Janos
Technology, Townshend VT, USA) which showed
negligible luminescence. The experimental data
were analysed by a model that assumes a continuous
distribution of lifetime values characterized by
Lorentzian shape centred at a time C and having a
width W. For this analysis the program minimizes
the reduced chi-square defined by an equation
reported elsewhere.
4 The temperature of the
samples was maintained at 37C with an external
bath circulator (Haake F3).
Statistical methods" The significance of the data
obtained were calculated according to Student’s
t-test.
Results
The background phospholipid fluorescence of
platelets at the used concentration was checked
prior to each measurement and was less than 0.5%
of the fluorescence when TMA-DPH was added. In
our conditions we tested if TMA-DPH in
unstimulated and PAF-stimulated platelets is
located in the outer monolayer of the plasma
membrane by dilution experiments. Immediately
after dilution of unstimulated and PAF-stimulated
platelets the fluorescence intensity completely
disappeared (data not shown), indicating that
TMA-DPH was located in the outer monolayer in
unstimulated platelets and that it had not crossed
the plasma membrane during stimulation with PAF.
In Fig. 1 TMA-DPH fluorescence anisotropy (rs)
in platelet membranes before and after PAF
addition (final concentration 10-7 M) is shown.
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FIG. 1. Steady-state fluorescence anisotropy (rs) of TMA-DPH at 37C
in platelets before and after PAF addition (10
-7 M). Values are expressed
as the mean -t- SD of ten samples. The rs increase after the addition of
PAF is significant (p < 0.01 ).
After the addition of PAF a time-limited and
significant (p < 0.01) increase in the rs value was
observed. After five minutes rs returned to the
baseline value. In the control sample (without PAF)
a stable and lasting r value was maintained during
the measurements. Incubation of PAF, at the
concentration used, with TMA-DPH in the absence
of platelets, did not produce detectable fluorescence
intensity. These data confirm that the observed r
increase was a consequence of PAF addition to
platelets. No changes in fluorescence intensity were
evident when PAF was added, indicating that the
addition of PAF did not induce platelet ag-
gregation. The absence of aggregation was further
checked with phase-contrast microscopy and by
single platelet counting.
Figure 2 shows the effect of PAF addition to
platelets in the presence of L-659,989. No
significant changes (p > 0.5) in rs value were
observed after the addition of PAF (10
-7 M).
Figure 3 shows the effect of PAF addition to
platelets in the presence of 1-O-hexadecyl-2-acetyl-
sn-glycero-3-phospho(N,N,N- trimethyl-hexanol-
amine.HiO. After addition of this PAF antagonist
to platelets a significant and stable decrease in r
value was observed. Consequent addition of PAF
(10-/M)induced no significant changes (p > 0.5)
in r value. Control experiments have demonstrated
that TMA-DPH labelled platelets, maintained at
37C for 10 min, showed an increase of rs after
addition of PAF. These data indicate that the effect
of PAF on platelets was blocked by the two
antagonists. The specificity of the two antagonists
was confirmed by activating antagonist-treated
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FIG. 2. Steady-state fluorescence anisotropy (rs) of TMA-DPH at 37C
in platelets before and after PAF addition (10-7 M) in the presence of
PAF antagonist L-659,989 (10
-6 M). Values are expressed as the
mean -I- SD of ten samples.
platelets with cz-thrombin (0.05 U/ml). Both ant-
agonists showed no inhibition on the increase of rs
induced by thrombin (data not shown).
Figures 4A and 4B show the results of the
lifetime distribution analysis of TMA-DPH decay
in platelet membranes in the absence and presence
of PAF, respectively. In the absence of PAF a two
component distribution has been found (Fig. 4A);
a long component with an average lifetime value
of 5.45 ns and a fractional intensity of 0.78, and a
short component with an average lifetime value of
1.24 ns and a fractional intensity of 0.22. The
distribution width was 0.18ns for the long
component and 0.09 ns for the short component.
The addition of PAF (10
-7 M) induced a 70%
decrease in distribution width of the long
component, but no effect on the average lifetime
value and fractional intensity was observed.
Distribution width, average lifetime, and fractional
intensity of the short component were not modified
by the addition of PAF.
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FIG. 3. Steady-state fluorescence anisotropy (rs) of TMA-DPH at 37C
in platelets before and after PAF addition (10
-7 M) in the presence of
PAF analogue 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho(N,N,N-
trimethyl)hexanol-amine.H20 (4 x 10 M). Values are expressed as the
mean +/- SD of ten samples.
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FIG. 4. TMA-DPH lifetime distribution in platelets before (A) and after
addition of PAF (10
-7 M) (B).
Discussion
Human platelets have both intra- and extra-
cellular specific PAF receptors. 6’1s’16 The interaction
of PAF with its specific extracellular receptor
triggers a complex cascade of biochemical events.
These events include the stimulation of GTPase,
17
transient elevation of intracellular Ca2+,
18 coupling
to both adenylate cyclase and phospholipase C,<9
and protein phosphorylation.
2 The response of
platelets to PAF is transient and PAF desensitizes
its receptor. This phenomenon of time-dependent
attenuation of responsiveness is common to many
receptor systems.6’2
The organization of cell membrane components
depends on a number of factors, including the
protein and lipid composition of the membrane,
receptor occupancies, and activities of membrane
proteins.
22 Cell membranes respond to stimuli and
integrate the enzymatic responses and functions by
rearrangement of membrane configuration. De-
pending on the nature of the stimulus and the state
of the membrane, different biochemical events take
place at the membrane level that influence
membrane organization. For example, the activa-
tion of membrane phospholipases produces rapid
changes in membrane phase behaviour, alteration
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in domains, and inhibition or activation of
membrane proteins.
22
In recent years fluorescent probes, such as DPH
and its cationic derivative TMA-DPH, have been
used widely in the study of the physico-chemical
state of biological membranes.23’24 Their photo-
physical properties are affected by the physico-
chemical changes of the microenvironment where
the probes are located. Because of its hydrophobic
structure, TMA-DPH incorporates into the mem-
brane but remains at the lipid-water interface
region with its cationic residue. TMA-DPH rs
reflects the packing of membrane lipid fatty acid
chains and can be related to the order parameter S,
if certain precautions are taken. 25’26 This packing
can change upon stimulation of certain cell
types .27,28
Our results indicate that PAF induces a
time-limited increase of lipid order in the exterior
prt of platelet membranes. In the presence of PAF
antagonists the described effect of PAF is totally
abolished. The TMA-DPH fluorescence lifetime
value is dependent on the dielectric constant of the
medium where it is embedded.
29 Therefore the
width of the lifetime distribution can be related to
the different physico-chemical properties of the
environment surrounding the probe. The distribu-
tion analysis, although based on phenomenological
ground, offers a good description of membrane
heterogeneity.7’13’14 In our distribution analysis it
was necessary to include a second component at a
shorter lifetime with a very low fractional intensity.
The origin of this second component is still
debated; for DPH this component has been referred
to as a photochemical derivative of the probe
3 or
alternatively it can represent a fraction of probe
molecules localized in a very polar environment.
31
In any case the relative fractional intensity of this
short component did not change significantly after
addition of PAF.
Our data for TMA-DPH lifetime distribution
show that PAF induced no changes in the central
lifetime value, whereas a narrowing in the
distribution width of the long component is
observed, indicating a decrease in the membrane
microheterogeneity. The observed changes in lipid
packing and in membrane heterogeneity in
activated platelets could result from modifications
in lipid metabolism through the activation of
endogenous phospholipases.6’19’2 An alternative
explanation could be based on a redistribution of
membrane proteins during activation.
32 In any case
a transition of the probe to a more homogeneous
environment seems to take place during PAF
activation.
Our study demonstrates that PAF interaction
with platelet membranes induces a time-limited
increase in lipid packing of the exterior part of the
membrane and a decrease in membrane hetero-
geneity. Because these changes in the physico-
chemical structure of the membrane can be blocked
by PAF antagonists, it seems likely that they are
attributed to PAF-receptor interaction and the
biochemical events associated with signal transduc-
tion.
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